{Reference Type}: Case Reports
{Title}: Posterior chamber implantation of a Preserflo Microshunt in a patient with a compromised endothelium.
{Author}: Martinez-de-la-Casa JM;Saenz-Frances F;Morales Fernandez L;García-Feijoo J;Martinez-de-la-Casa JM;Saenz-Frances F;Morales Fernandez L;García-Feijoo J;
{Journal}: Arch Soc Esp Oftalmol (Engl Ed)
{Volume}: 97
{Issue}: 3
{Year}: Mar 2022
暂无{DOI}: 10.1016/j.oftale.2022.02.002
{Abstract}: The objective of the present case is to describe a variation in the Preserflo Microshunt surgical technique, placing it in the posterior chamber to minimise the risk of endothelial cell loss in cases with a compromised endothelium. The patient was a 72-year-old pseudophakic woman, with granular dystrophy and a primary diagnosis of open-angle glaucoma presenting with a progressive visual field defect and an IOP of 26 mmHg with maximal medical therapy. The cornea had incipient stromal folds with an endothelial count of 700 cells/mm2. A Preserflo Microshunt was implanted in the posterior chamber to minimise the possibility of further damage to the corneal endothelium. Six months after surgery, the implant remains functional. The IOP is 9 mmHg without medications. As far as we know, this is the first Preserflo implanted in the posterior chamber described in the literature.